Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma.
Khan T, He Y, Kryza T, Harrington BS, Gunter JH, Sullivan MA, Cuda T, Rogers R, Davies CM, Broomfield A, Gough M, Wu AC, McGann T, Weroha SJ, Haluska P, Forbes JM, Armes JE, Barry SC, Coward JI, Jagasia N, Chetty N, Snell CE, Lourie R, Perrin LC, Hooper JD. Khan T, et al. Among authors: coward ji. Cancers (Basel). 2020 Apr 3;12(4):869. doi: 10.3390/cancers12040869. Cancers (Basel). 2020. PMID: 32260077 Free PMC article.
EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface.
Adams MN, Harrington BS, He Y, Davies CM, Wallace SJ, Chetty NP, Crandon AJ, Oliveira NB, Shannon CM, Coward JI, Lumley JW, Perrin LC, Armes JE, Hooper JD. Adams MN, et al. Among authors: coward ji. Oncogene. 2015 Mar 12;34(11):1375-83. doi: 10.1038/onc.2014.88. Epub 2014 Mar 31. Oncogene. 2015. PMID: 24681947
Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.
He Y, Wu AC, Harrington BS, Davies CM, Wallace SJ, Adams MN, Palmer JS, Roche DK, Hollier BG, Westbrook TF, Hamidi H, Konecny GE, Winterhoff B, Chetty NP, Crandon AJ, Oliveira NB, Shannon CM, Tinker AV, Gilks CB, Coward JI, Lumley JW, Perrin LC, Armes JE, Hooper JD. He Y, et al. Among authors: coward ji. Oncogene. 2016 Jan 28;35(4):468-78. doi: 10.1038/onc.2015.101. Epub 2015 Apr 20. Oncogene. 2016. PMID: 25893298
Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.
Harrington BS, He Y, Davies CM, Wallace SJ, Adams MN, Beaven EA, Roche DK, Kennedy C, Chetty NP, Crandon AJ, Flatley C, Oliveira NB, Shannon CM, deFazio A, Tinker AV, Gilks CB, Gabrielli B, Brennan DJ, Coward JI, Armes JE, Perrin LC, Hooper JD. Harrington BS, et al. Among authors: coward ji. Br J Cancer. 2016 Feb 16;114(4):417-26. doi: 10.1038/bjc.2015.471. Epub 2016 Feb 4. Br J Cancer. 2016. PMID: 26882065 Free PMC article.
L1 Retrotransposon Heterogeneity in Ovarian Tumor Cell Evolution.
Nguyen THM, Carreira PE, Sanchez-Luque FJ, Schauer SN, Fagg AC, Richardson SR, Davies CM, Jesuadian JS, Kempen MHC, Troskie RL, James C, Beaven EA, Wallis TP, Coward JIG, Chetty NP, Crandon AJ, Venter DJ, Armes JE, Perrin LC, Hooper JD, Ewing AD, Upton KR, Faulkner GJ. Nguyen THM, et al. Among authors: coward jig. Cell Rep. 2018 Jun 26;23(13):3730-3740. doi: 10.1016/j.celrep.2018.05.090. Cell Rep. 2018. PMID: 29949758 Free article.
Safety and feasibility of hyperthermic intraperitoneal chemotherapy during interval cytoreductive surgery in patients with advanced high-grade serous ovarian, fallopian tube, peritoneal cancer in an Australian context.
Samoylovich A, Jennings B, Shannon C, Coward JI, Lourie R, Riordan J, Lai NA, van Driel WJ, Cabraal N, Jagasia N, Chetty N, Naidu S, Perrin LC, Barry SC. Samoylovich A, et al. Among authors: coward ji. Aust N Z J Obstet Gynaecol. 2023 Oct;63(5):702-708. doi: 10.1111/ajo.13694. Epub 2023 May 31. Aust N Z J Obstet Gynaecol. 2023. PMID: 37259677
Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci.
DeVries AA, Dennis J, Tyrer JP, Peng PC, Coetzee SG, Reyes AL, Plummer JT, Davis BD, Chen SS, Dezem FS, Aben KKH, Anton-Culver H, Antonenkova NN, Beckmann MW, Beeghly-Fadiel A, Berchuck A, Bogdanova NV, Bogdanova-Markov N, Brenton JD, Butzow R, Campbell I, Chang-Claude J, Chenevix-Trench G, Cook LS, DeFazio A, Doherty JA, Dörk T, Eccles DM, Eliassen AH, Fasching PA, Fortner RT, Giles GG, Goode EL, Goodman MT, Gronwald J; OPAL Study Group; AOCS Group; Håkansson N, Hildebrandt MAT, Huff C, Huntsman DG, Jensen A, Kar S, Karlan BY, Khusnutdinova EK, Kiemeney LA, Kjaer SK, Kupryjanczyk J, Labrie M, Lambrechts D, Le ND, Lubiński J, May T, Menon U, Milne RL, Modugno F, Monteiro AN, Moysich KB, Odunsi K, Olsson H, Pearce CL, Pejovic T, Ramus SJ, Riboli E, Riggan MJ, Romieu I, Sandler DP, Schildkraut JM, Setiawan VW, Sieh W, Song H, Sutphen R, Terry KL, Thompson PJ, Titus L, Tworoger SS, Van Nieuwenhuysen E, Edwards DV, Webb PM, Wentzensen N, Whittemore AS, Wolk A, Wu AH, Ziogas A, Freedman ML, Lawrenson K, Pharoah PDP, Easton DF, Gayther SA, Jones MR. DeVries AA, et al. J Natl Cancer Inst. 2022 Nov 14;114(11):1533-1544. doi: 10.1093/jnci/djac160. J Natl Cancer Inst. 2022. PMID: 36210504 Free PMC article.
Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA).
Smith D, Robledo KP, Yip S, Cummins MM, Kok PS, Lee YC, Friedlander M, Baron-Hay S, Shannon C, Coward J, Beale P, Goss G, Meniawy T, Lombard J, Spurdle AB, Andrews J, Stockler MR, Mileshkin L, Antill Y; Australia New Zealand Gynaecological Oncology Group (ANZGOG). Smith D, et al. Cancers (Basel). 2022 Dec 30;15(1):254. doi: 10.3390/cancers15010254. Cancers (Basel). 2022. PMID: 36612250 Free PMC article.
47 results